These data indicate that HER2-low ApoCa shares similar molecular features to other ApoCa subtypes and aligns with the recent data from NST carcinomas that revealed that HER2-low is not a distinct clinical and molecular subtype of breast cancer [29–32]. This evidence concerns the gene ERBB2 and carcinoma.